As of April 28, 2026, Atea Pharmaceuticals's top three insider holders are Jean-Pierre Sommadossi (President, Ceo, And Chairman, 5.87Mn shares), Jean-Pierre Sommadossi (President, Ceo, And Chairman, 767.83K shares), Janet Mj Hammond (Chief Development Officer, 127.67K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Jean-Pierre Sommadossi | President, Ceo, And Chairman | 0 | 5,866,025 | 19 Sep, 2024 |
| Jean-Pierre Sommadossi | President, Ceo, And Chairman | 767,830 | 0 | 03 Feb, 2026 |
| Janet Mj Hammond | Chief Development Officer | 127,665 | 0 | 03 Feb, 2026 |
| Bruno Lucidi | - | 112,750 | 0 | 24 Jun, 2025 |
| Maria Arantxa Horga | Chief Medical Officer | 96,086 | 0 | 03 Feb, 2026 |
| Polly A. Murphy | - | 86,045 | 0 | 24 Jun, 2025 |
| John Vavricka | Chief Commercial Officer | 82,594 | 0 | 03 Feb, 2026 |
| Jerome M. Adams | - | 62,750 | 0 | 24 Jun, 2025 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 31 Jan, 2026 | Maria Arantxa Horga | Common Stock | A | 51,283 | - | 112,159 | D | M |
| 31 Jan, 2026 | John Vavricka | Common Stock | A | 42,083 | - | 94,164 | D | M |
| 31 Jan, 2026 | Jean-Pierre Sommadossi | Common Stock | A | 272,983 | - | 573,923 | D | M |
| 31 Jan, 2026 | Janet Mj Hammond | Common Stock | A | 58,050 | - | 141,801 | D | M |
| 31 Jan, 2026 | John Vavricka | Common Stock | D | 11,570 | $4.24 | 82,594 | D | F |
| 31 Jan, 2026 | Janet Mj Hammond | Common Stock | D | 14,136 | $4.24 | 127,665 | D | F |
| 31 Jan, 2026 | Maria Arantxa Horga | Common Stock | D | 16,073 | $4.24 | 96,086 | D | F |
| 31 Jan, 2026 | Jean-Pierre Sommadossi | Common Stock | D | 106,093 | $4.24 | 467,830 | D | F |
| 31 Jan, 2026 | Janet Mj Hammond | Restricted Stock Units | D | 46,800 | $0.00 | 0 | D | M |
| 03 Feb, 2026 | Jean-Pierre Sommadossi | Common Stock | A | 300,000 | $1.24 | 767,830 | D | M |
| 31 Jan, 2026 | Maria Arantxa Horga | Restricted Stock Units | D | 41,533 | $0.00 | 0 | D | M |
| 31 Jan, 2026 | John Vavricka | Restricted Stock Units | D | 33,333 | $0.00 | 0 | D | M |
| 31 Jan, 2026 | Maria Arantxa Horga | Restricted Stock Units | D | 9,750 | $0.00 | 0 | D | M |
| 31 Jan, 2026 | Janet Mj Hammond | Restricted Stock Units | D | 11,250 | $0.00 | 0 | D | M |
| 31 Jan, 2026 | John Vavricka | Restricted Stock Units | D | 8,750 | $0.00 | 0 | D | M |
| 31 Jan, 2026 | Jean-Pierre Sommadossi | Restricted Stock Units | D | 173,466 | $0.00 | 0 | D | M |
| 31 Jan, 2026 | Janet Mj Hammond | Stock Option (Right to Buy) | A | 177,000 | $0.00 | 177,000 | D | A |
| 31 Jan, 2026 | Maria Arantxa Horga | Stock Option (Right to Buy) | A | 173,500 | $0.00 | 173,500 | D | A |
| 31 Jan, 2026 | Jean-Pierre Sommadossi | Restricted Stock Units | D | 99,517 | $0.00 | 0 | D | M |
| 31 Jan, 2026 | John Vavricka | Stock Option (Right to Buy) | A | 119,520 | $0.00 | 119,520 | D | A |